Nusinersen (Spinraza)
Nusinersen (Spinraza)
Page last updated: 3rd September 2026
High Dose Nusinersen (Spinraza)
On 14th April 2026 UK Medicines and Healthcare products Regulatory Agency (MHRA) Approved New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
The new high dose, delivered via lumber puncture, will have a more rapid loading phase than the current dose people in the UK receive. There will be two 50 mg loading doses administered 14 days apart. There will then be 28 mg maintenance dose injections every four months. Following the publication of NICE’s Multiple Technology Appraisal (MTA) guidance on 4 June 2026, the higher-dose regimen of nusinersen (50/28 mg) is now routinely commissioned through the NHS in England, Wales and Northern Ireland for the treatment of 5q SMA.
For more information about access to high dose Spinraza across the UK, read our community letter from Biogen or talk to your healthcare team.
Nusinersen clinical trials and their results
Researchers have tested nusinersen in human clinical trials since 2011. Nusinersen is not a cure for 5q SMA but in these trials, it has been consistently shown to have an acceptable safety profile and to be well-tolerated. When compared to no treatment, it has led to clinically meaningful improvements in muscle function. Several trials of nusinersen are still ongoing.
Read more >